BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers.
BerGenBio is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance “ the cause of approximately 90 percent of cancer deaths.
BerGenBio was founded in 2007 & is based in Bergen, Hordaland, Norway.
BerGenBio’s phase II programme is focussed on establishing proof of concept that bemcentinib may reverse and prevent resistance to immune, targeted and chemotherapy thus positioning bemcentinib as a potential future cornerstone to cancer therapy. Six phase II trials are ongoing across oncology indications with high unmet medical need.
BerGenBio is leveraging its solid leadership position in understanding the role of AXL and related kinase signalling in disease of high unmet need to develop a diversified pipeline of selective AXL inhibitors, including biologics and small molecules.